Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).

被引：4
|
作者：
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] West Virginia Univ, Morgantown, WV USA
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14019
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
    Topp, M. S.
    van Meerten, T.
    Wermke, M.
    Lugtenburg, P. J.
    Minnema, M. C.
    Song, K. W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
  • [22] CLINICAL PREDICTORS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS
    Sanderson, R.
    Munoz, J.
    Wang, Y.
    Kanters, S.
    Limbrick-Oldfield, E.
    Miao, H.
    Spooner, C.
    Baro, E.
    Xu, H.
    Jacobson, C.
    VALUE IN HEALTH, 2022, 25 (12) : S47 - S48
  • [23] Long-term (5 year) overall survival in zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large b-cell lymphoma (LBCL)
    Jacobson, C. A.
    Locke, F. L.
    Ghobadi, A.
    Miklos, D. B.
    Lekakis, L. J.
    Oluwole, O. O.
    Lin, Y.
    Hill, B. T.
    Timmerman, J. M.
    Deol, A.
    Reagan, P. M.
    Stiff, P.
    Flinn, I. W.
    Farooq, U.
    Goy, A. H.
    Munoz, J.
    Siddiqi, T.
    Shen, R. R.
    Bot, A. A.
    Dong, J.
    Singh, K.
    Spooner, C.
    Karalliyadda, R.
    Kim, J. J.
    Zheng, Y.
    Neelapu, S. S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 131 - 132
  • [24] Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)
    Mian, Agrima
    Wei, Wei
    Hill, Brian T.
    Hamilton, Betty K.
    Pohlman, Brad
    Jagadeesh, Deepa
    Anwer, Faiz
    Kalaycio, Matt E.
    Dean, Robert M.
    Sobecks, Ronald M.
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S44 - S45
  • [25] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [26] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Maloney, David G.
    Kuruvilla, John
    Fox, Christopher P.
    Cartron, Guillaume
    Li, Daniel
    Hasskarl, Jens
    Bonner, Ashley
    Zhang, Yixie
    Liu, Fei Fei
    BLOOD, 2020, 136
  • [27] Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
    Ahmed, Sairah
    Furqan, Fateeha
    Strati, Paolo
    Westin, Jason
    Fayad, Luis
    Hagemeister, Frederick B.
    Lee, Hun Ju
    Iyer, Swaminathan Padmanabhan
    Nair, Ranjit
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Steiner, Raphael
    Wang, Michael
    Pinnix, Chelsea Camille
    Flowers, Christopher
    Horowitz, Sandra B.
    Hawkins, Misha
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
    Neelapu, Sattva Swarup
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David Bernard
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [30] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Lee, Dasom
    Kambhampati, Swetha
    Bobillo, Maria Silvina Odstrcil
    Adedokun, Babatunde
    Shadman, Mazyar
    Olson, Amanda L.
    Herrera, Alex F.
    Lee, Catherine J.
    Jacobson, Caron A.
    Bye, Matthew
    Hamadani, Mehdi
    Kim, Soyoung
    Dahiya, Saurabh
    Hu, Zhen-Huan
    Speth, Kelly
    To, Christina
    Mirjah, Debbie L.
    Best, Timothy
    Locke, Frederick L.
    Ahmed, Nausheen
    Tees, Michael T.
    Pasquini, Marcelo C.
    Ahmed, Sairah
    BLOOD, 2024, 144 : 527 - 528
12345